Literature DB >> 10083554

Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival.

C Rastellini1, A Salam, R Kuddus, A Aitouche, V Subbotin, M Braun, R Leach, R Peach, J J Fung, T E Starzl, A S Rao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10083554      PMCID： PMC2975556          DOI： 10.1016/s0041-1345(98)01979-4

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

1.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.

Authors:  C P Larsen; E T Elwood; D Z Alexander; S C Ritchie; R Hendrix; C Tucker-Burden; H R Cho; A Aruffo; D Hollenbaugh; P S Linsley; K J Winn; T C Pearson
Journal:  Nature       Date:  1996-05-30       Impact factor: 49.962

2.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.

Authors:  A D Kirk; D M Harlan; N N Armstrong; T A Davis; Y Dong; G S Gray; X Hong; D Thomas; J H Fechner; S J Knechtle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

3.  Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation.

Authors:  M G Levisetti; P A Padrid; G L Szot; N Mittal; S M Meehan; C L Wardrip; G S Gray; D S Bruce; J R Thistlethwaite; J A Bluestone
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422
  3 in total
  1 in total

1.  Alloreactive (CD4-Independent) CD8+ T cells jeopardize long-term survival of intrahepatic islet allografts.

Authors:  K E Lunsford; K Jayanshankar; A M Eiring; P H Horne; M A Koester; D Gao; G L Bumgardner
Journal:  Am J Transplant       Date:  2008-06       Impact factor: 8.086
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.